ProBioGen Announces Further Development Milestone for Use of Its GlymaxX® Cancer Cell-Killing Enhancement Antibody Technology with Merus N.V.
ProBioGen signs Second Contract Development Agreement with Tizona Therapeutics for Immuno-Oncology Antibody Project
ProBioGen grants a license for human lymph node technology to TissUse for Multi-Organ-Chip applications
Merus N.V. Signs Commercial Multi-Product License for ProBioGen’s GlymaxX® ADCC Enhancement Technology
ProBioGen Will License GlymaxX® to Thermo Fisher Scientific for Use in Developing Allergy Diagnostics